CONy 2022 | Elucidating the pathology of post COVID-19 headaches
Dimos-Dimitrios Mitsikostas, MD, PhD, National & Kapodistrian University of Athens, Athens, Greece, discusses the phenomenon of post COVID-19 headaches and whether they are secondary headaches or a worsening of existing headaches. An increase of headaches as result of COVID-19 infection or vaccination has been observed and for a number of patients, headaches lasting longer than 30 days as a result of long COVID have been reported. Several studies have additionally indicated that during infection, levels of particular cytokines increase, exacerbating the severity of headaches. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
Disclosures
Prof. Mitsikostas has received consulting, speaking fees and travel grants from Allergan, Amgen, Bayer, Biogen, Cefaly, Genesis Pharma, GlaxoSmithKline, ElectroCore, Eli Lilly, Merck-Serono, Merz, Mylan, Novartis, Roche, Sanofi- Genzyme, Specifar and Teva; Participated as principal investigator in randomised trials sponsored by Amgen, Eli-Lilly, ElectroCore, Merz, Novartis, Lundbeck, and Teva; Currently president of the Hellenic Headache Society, Co-Chairman of the Headache Scientific Panel at the European Academy of Neurology, and Co-Chairman of the Headache Section at CONy.
